{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 459852163
| IUPAC_name = [1-(cyclohexylmethyl)-7-methoxyindol-3-yl]-[(3S)-3,4-dimethylpiperazin-1-yl]methanone
| image = Org28611_structure.png
| width = 200

<!--Clinical data-->
| tradename =  
| legal_CA = Schedule II
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 639068-99-8 
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1209709
| PubChem = 10091392
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8266929

<!--Chemical data-->
| C=23 | H=33 | N=3 | O=2 
| molecular_weight = 383.526 g/mol
| smiles = COc3cccc(c13)c(C(=O)N(CC2C)CCN2C)cn1CC4CCCCC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H33N3O2/c1-17-14-25(13-12-24(17)2)23(27)20-16-26(15-18-8-5-4-6-9-18)22-19(20)10-7-11-21(22)28-3/h7,10-11,16-18H,4-6,8-9,12-15H2,1-3H3/t17-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ONXJNAIZJKLJGA-KRWDZBQOSA-N
}}

'''Org 28611''' ('''SCH-900,111''')  is a drug developed by [[Organon International]] which acts as a potent [[cannabinoid]] [[Receptor (biochemistry)|receptor]] [[full agonist]] at both the [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] receptors. It was developed with the aim of finding a [[solubility|water-soluble]] cannabinoid agonist suitable for [[intravenous]] use as an [[analgesic]],<ref>{{Cite journal |author= Adam, J. M.|title= Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists |doi= 10.1039/c0md00022a |journal= [[MedChemComm]]|publisher= [[Royal Society of Chemistry]]|volume= 1 |pages= 54 |year= 2010 |display-authors=etal}}</ref> and while it achieved this aim and has progressed as far as Phase II [[clinical trial]]s in humans as both a [[sedative]] and an [[analgesic]], results against the comparison drugs ([[midazolam]] and [[morphine]] respectively) were not particularly favourable in initial testing.<ref name="pmid18635703">{{cite journal |vauthors=Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF, van Gerven JM |title=Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers |journal=Journal of Psychopharmacology (Oxford, England) |volume=23 |issue=6 |pages=633–44 |date=August 2009 |pmid=18635703 |doi=10.1177/0269881108091551 |url=}}</ref><ref>[http://clinicaltrials.gov/ct2/show/NCT00782951 A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery]</ref>

==See also==
* [[LBP-1 (drug)|LBP-1]]
* [[N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide]]
* [[Org 28312]]

== References ==
<references />

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indoles]]
[[Category:Piperazines]]


{{cannabinoid-stub}}